Last reviewed · How we verify
Apsen Farmaceutica S.A. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
7 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Tramal® | Tramal® | marketed | Synthetic opioid analgesic | Mu opioid receptor; norepinephrine transporter; serotonin transporter | Pain Management | |
| Toragesic® | Toragesic® | phase 3 | NSAID | COX-2 | Pain management | |
| APSCTC | APSCTC | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 1
- Oncology · 1
- Pain Management · 1
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Pfizer · 2 shared drug classes
- Allergan · 2 shared drug classes
- AstraZeneca · 2 shared drug classes
- Novartis · 2 shared drug classes
- Strategic Science & Technologies, LLC · 2 shared drug classes
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Apsen Farmaceutica S.A.:
- Apsen Farmaceutica S.A. pipeline updates — RSS
- Apsen Farmaceutica S.A. pipeline updates — Atom
- Apsen Farmaceutica S.A. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Apsen Farmaceutica S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/apsen-farmaceutica-s-a. Accessed 2026-05-16.